Oncogenes

Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Cell Cycle, Cyclin-dependent kinase 4, Oncogenes, Proteins, Cancer, Biology

Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system.

Key Points: 
  • Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system.
  • Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer.
  • The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
  • Onconova is in preclinical development with its novel, proprietary, CDK4/6 + ARK5 inhibitor, ON 123300.

OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib

Retrieved on: 
Monday, September 21, 2020
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer, Oncogenes, Melanoma, RTT, Ras GTPase, BRAF, Targeted therapy, Binimetinib, Vemurafenib

Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations.

Key Points: 
  • Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations.
  • An unmet medical need remains for targeted therapy in metastatic patients harboring an NRAS mutation.
  • reported in Cancer Discovery, as well as preclinical combination studies conducted by OnKure, the rational combination of these two agents may enhance clinical benefit of MAPK inhibition in NRAS melanomas.
  • OnKure and Pfizer will form a Joint Development Committee to review clinical trial results from the OnKure-sponsored study.

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Retrieved on: 
Monday, September 21, 2020
Branches of biology, Catalysis, Chemistry, Biology, Proteins, Metabolism, Cell Cycle, Cyclin-dependent kinase 4, Oncogenes, CD134, Enzyme, Oncogene

In December 2017, Onconova entered into an agreement with HanX Biopharmaceuticals for the development, registration, and commercialization of ON 123300 in China.

Key Points: 
  • In December 2017, Onconova entered into an agreement with HanX Biopharmaceuticals for the development, registration, and commercialization of ON 123300 in China.
  • ON 123300 is a novel small molecule, and a dual inhibitor of CDK4/6 and ARK5, a key enzyme controlling cellular energy homeostasis.
  • Inhibition of ARK5 by ON 123300 results in the collapse of oncogene-altered energy metabolism, leading to programmed cell death.
  • HanX is an oncology specialty company with an innovative pipeline targeting PD1, VEGFR, OX40 in clinical and pre-clinical stages.

Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020

Retrieved on: 
Thursday, September 17, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Epidermal growth factor receptor, Oncogenes, Adverse event, ESMO, Oncology, Organic compounds, Quinazolines, Chemical compounds, Branches of biology

Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clinical trial evaluating CLN-081 for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) will be presented as a poster presentation at the ESMO Virtual Congress 2020.

Key Points: 
  • Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clinical trial evaluating CLN-081 for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) will be presented as a poster presentation at the ESMO Virtual Congress 2020.
  • Session Date & Time: From 09:00 Thursday, 17 September 2020 until 20:00 Monday, 21 September 2020.
  • CLN-081 demonstrated acceptable safety, with no dose-limiting toxicities (DLT) and no Grade 3 or greater drug-related adverse events.
  • The most common drug-related adverse events included rash and dry skin, with only one case of Grade 1 drug-related diarrhea being observed.

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

Retrieved on: 
Wednesday, September 16, 2020
Oncogenes, Ras GTPase, Branches of biology, Cancer, KRAS, Causes of death, Clinical medicine

Revolution Medicines uses its proprietary tri-complex technology platform to create innovative compounds designed to inhibit the active, GTP-bound form of RAS, or RAS(ON), proteins.

Key Points: 
  • Revolution Medicines uses its proprietary tri-complex technology platform to create innovative compounds designed to inhibit the active, GTP-bound form of RAS, or RAS(ON), proteins.
  • The company previously reported representative preclinical profiles of its potent inhibitors of another common cancer driver, KRASG12C(ON).
  • The newly presented data demonstrated that its KRASG12D(ON) inhibitors induced significant decreases in tumor volume in a xenograft model of human pancreatic cancer driven by a KRASG12D mutation.
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.

Kanazawa University research: Potential drug treatment for particular type of lung-cancer

Retrieved on: 
Wednesday, September 16, 2020
Lung cancer, Tyrosine kinase receptors, Organic compounds, Chemical compounds, Cancer, Epidermal growth factor receptor, Oncogenes, Osimertinib, AXL receptor tyrosine kinase

KANAZAWA, Japan, Sept. 16, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

Key Points: 
  • KANAZAWA, Japan, Sept. 16, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.
  • Now, Seiji Yano from Kanazawa University and colleagues have investigated the efficacy of the TKI osimertinib for treating EGFR-mutated lung cancer, and how it relates to the expression in tumor cells of a particular protein called AXL.
  • Moreover, the researchers suggest a way to enhance the success of osimertinib treatment for the case of AXL-low expressing tumors.
  • Seiji Yano from Kanazawa University and colleagues have found that this is also the case for EGFR-mutated lung cancer.

Kanazawa University research: Potential drug treatment for particular type of lung-cancer

Retrieved on: 
Wednesday, September 16, 2020
Lung cancer, Tyrosine kinase receptors, Organic compounds, Chemical compounds, Cancer, Epidermal growth factor receptor, Oncogenes, Osimertinib, AXL receptor tyrosine kinase

KANAZAWA, Japan, Sept. 16, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

Key Points: 
  • KANAZAWA, Japan, Sept. 16, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.
  • Now, Seiji Yano from Kanazawa University and colleagues have investigated the efficacy of the TKI osimertinib for treating EGFR-mutated lung cancer, and how it relates to the expression in tumor cells of a particular protein called AXL.
  • Moreover, the researchers suggest a way to enhance the success of osimertinib treatment for the case of AXL-low expressing tumors.
  • Seiji Yano from Kanazawa University and colleagues have found that this is also the case for EGFR-mutated lung cancer.

OCTIMET partners OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China

Retrieved on: 
Wednesday, September 16, 2020
Enzymes, Tyrosine kinase receptors, Organic compounds, Chemical compounds, Lung cancer, Quinazolines, Epidermal growth factor receptor, Oncogenes, Tyrosine kinase inhibitors, Tyrosine kinase, Receptor tyrosine kinase, Non-small-cell lung carcinoma

Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist's third generation EGFR TKI Furmonertinib (AST2818).

Key Points: 
  • Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist's third generation EGFR TKI Furmonertinib (AST2818).
  • In China, more than 38% of NSCLC patients harbor activating EGFR mutations, making the region ideal for completing expanded clinical efficacy studies more rapidly whilst addressing a large potential market.
  • "We are proud to have Shanghai Allist Pharmaceuticals Co., Ltd. as a partner in developing this exciting therapeutic agent," said Shelley Margetson, Chief Executive Officer of OCTIMET.
  • OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase (RTK).

OCTIMET partners OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China

Retrieved on: 
Wednesday, September 16, 2020
Enzymes, Tyrosine kinase receptors, Organic compounds, Chemical compounds, Lung cancer, Quinazolines, Epidermal growth factor receptor, Oncogenes, Tyrosine kinase inhibitors, Tyrosine kinase, Receptor tyrosine kinase, Non-small-cell lung carcinoma

Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist's third generation EGFR TKI Furmonertinib (AST2818).

Key Points: 
  • Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist's third generation EGFR TKI Furmonertinib (AST2818).
  • In China, more than 38% of NSCLC patients harbor activating EGFR mutations, making the region ideal for completing expanded clinical efficacy studies more rapidly whilst addressing a large potential market.
  • "We are proud to have Shanghai Allist Pharmaceuticals Co., Ltd. as a partner in developing this exciting therapeutic agent," said Shelley Margetson, Chief Executive Officer of OCTIMET.
  • OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase (RTK).

G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress

Retrieved on: 
Monday, September 14, 2020
Cell Cycle, Cyclin-dependent kinase 4, Oncogenes, Proteins, G1, Garbage-first collector

G1 abstract titles are below; more details are available on the ESMO Virtual Congress 2020 website .

Key Points: 
  • G1 abstract titles are below; more details are available on the ESMO Virtual Congress 2020 website .
  • EQRx and Genor are responsible for all costs related to the development and commercialization of lerociclib in their respective territories.
  • In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .